Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the tirzepatide treatment on coronary atherosclerosis progression: The (T-Plaque) randomized-controlled trial design

What Was Tested

Researchers studied Tirzepatide in this clinical study publication.

The goal of this trial is to assess how tirzepatide affects the progression of atherosclerotic plaque as determined by multidetector computed tomography angiography (MDCTA).

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.

Patients will undergo quarterly visits for safety assessments and labs, and follow up with repeat CCTA at 1 year.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Tirzepatide study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Tirzepatide group a baseline to be compared against.

More than one site took part, so the participants came from several places.

This trial is a double blind, randomized, prospective, placebo-controlled multicenter phase IV trial.

Baseline examination will include the results of their demographics, lab tests, coronary calcium, as well as coronary plaque volume/composition.

What Was Measured

Topics PubMed links to this paper include Computed Tomography Angiography, Coronary Angiography, Coronary Artery Disease, Diabetes Mellitus, Type 2, Disease Progression, Multidetector Computed Tomography and Plaque, Atherosclerotic.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (American heart journal), a journal based in United States.

More context: the Tirzepatide compound page, all human trials.